A randomized, placebo-controlled trial found the selective serotonin reuptake inhibitor improved fatigue severity vs placebo, while metformin showed no evidence of benefit.
Diffuse alveolar hemorrhage with coexistent antiphospholipid syndrome complicated anticoagulation therapy and created competing bleeding and thrombosis risks.